Abstract
TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with specific genomic alterations. Results in a cohort of pts with solid tumors with BRCA1/2 mut treated with O are reported.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have